饶议科学

趣

Image
Image
Image
Image
Image
Image
Image
Image
Image
Image
Image
Image

1. Starr A, Ruks M, GiannelisA, et al. (2026). Within- and between-family genetic effects on educational achievement vary across countries and ages. Molecular Psychiatry31:2029–2037. 

2. ShamsanGA, LiuCJ, BramanBC,et al. (2026). Differential migration mechanics and immune responses of glioblastoma subtypes. bioRxiv 2022.06.26.497270.

3. Simental-RamosA, ChomettonS, JungA, et al. (2026).An enzymatic–metabolic sensing axis in taste cells detects glucose-yielding carbohydrates. bioRxiv 2026.03.13.710876.

4. Spence H, Read FL, Waldron FM, Gregory JM. (2026). Metabolic signatures of ferritin and TDP-43 co-pathology provide a mechanistic basis for stratified therapeutic approaches in ALS. bioRxiv 2026.03.13.711539.

5. SaitoY, NamieT, NaoiM, NakamuraTJ. (2026).Lack of Period1 accelerates colorectal tumorigenesis in ApcMin/+ mice. bioRxiv 2026.03.12.711485.

6. Fodder K, Smith HM, Yaman U,et al. (2026). Early oligodendrocyte dysfunction signature in Alzheimer’s disease: Insights from DNA methylomics and transcriptomics. bioRxiv 2025.08.28.672821.

7. Fenstermacher SJ, Vonasek AN, Cavanagh AE, et al.(2026). Potentiation of active locomotor state by spinal-projecting serotonergic neurons. Neuron 114:1117-1130.e4

8. Zheng C, Liu X, Wei A, et al. (2026). Converging dopamine pathways onto basolateral amygdala neurons encode exploration decisions. Neuron 114:1131–1151.e6. 

9. Smith JE, Cardigan R, Sanderson E, et al.  (2026). Prehospital Whole Blood in Traumatic Hemorrhage - a Randomized Controlled Trial.  New England Journal of Medicine, 10.1056/NEJMoa2516043. Advance online publication.

10. Hanke J, Ojeda SP, Cheong RW, et al. (2026). OmniBind: Proteome-Wide Promiscuity Predictions for Early-Stage Drug Screening. bioRxiv 2026.03.17.712433.  

11. Cataldi J, Pelentritou A, Schwartz S, Lucial MD. (2026). Sensory processing reallocation from external to internal signals in REM sleep. bioRxiv 2026.03.16.712081.

12. Li C, Gong L, Song C, et al. (2026). Multi-timescale Computation by Astrocytes. bioRxiv 2026.01.05.697758.

13. Wang X, Song J, Lin J, et al. (2026). Heterogeneous and specific localization of mRNAs at dendritic spine and its dependence on microtubule entry. bioRxiv 2026.02.13.705666.

17. Cho B, Youngstrom DE, Killiany S, et al.(2026). Sleep-dependent clearance of brain lipids by peripheral blood cells.Nature 651:720–731. 

18. Gaudi AU, Meier M, Baltaci OF, et al.(2026). Convergent evolution of scavenger cell development at brain borders.Nature 651:743–751. 

19. Zink A, Dai DF, Wittich A, et al.(2026). Pluripotent stem-cell-based screening uncovers sildenafil as a mitochondrial disease therapy.Cell189:1656–1679.e42. 

20. Körner J, Howard D, Solinski HJ, et al. (2026). Molecular architecture of human dermal sleeping nociceptors. Cell189:1820–1835.e22. 

21. Zhu K, Li WC, Liu J, et al.(2026). Functional landscape of non-canonical open reading frames in coordinating cell fate.Molecular Cell 86:1081–1098.e14. 

22. Ritacco DA, Shahnawaz H, Oduguwa A, et al.(2026). The human antibacterial factor APOL3 couples lysosomal damage to mitochondrial DNA efflux and type I IFN induction.Molecular Cell86:1116–1133.e8. 

23. Garbett KA, Zheng C, DrubeJ, et al. (2026). Cytoplasmic tail diversity determines the effector bias of the adhesion GPCR ADGRL2.Cell Chemical Biology 33:364–378.e6. 

24. Zhang JZ, Li X, Batingana AR, et al. (2025). De novo design of Ras isoform selective binders. bioRxiv , 2024.08.29.610300. 

25. Liu Y, Li Y, Yu T, et al.(2026). Discovery of MARK2 as a physiological kinase for PER2 in the mammalian clock.Cell Chemical Biology33:379–395.e6.

26. Y Wu, Y Lan, MA Allred, et al.(2026). Mitotically Driven Cytoskeletal Reorganization Governs Zebrafish Left-Right Organizer Detachment from EVL and Lumen Morphogenesis. bioRxiv 2026.03.18.712746.

27. SeerleyAL, RothfussMT, GrayBM, et al. (2026). Novel Prion Protein Gene (PRNP) Variants in Wild Montana Mule Deer, bioRxiv 2026.03.17.711390.

28. Mabrouk OS, Tichler B, Arnold HM, et al. (2026). LRRK2-targeting antisense oligonucleotide in Parkinson's disease: a phase 1 randomized controlled trial.Nature Medicine, 10.1038/s41591-026-04262-4. Advance online publication. 

Image